Skip to content

Study · Observational study · n = 82 · 2021

4 results

Once-weekly subcutaneous semaglutide treatment for persons with type 2 diabetes: Real-world data from a diabetes out-patient clinic.

Hansen KB, Svendstrup M, Lund A, Knop FK, Vilsbøll T, Vestergaard H

Diabetic medicine : a journal of the British Diabetic Association4 Aug 2021Cited by 21 (Europe PMC)

PMID34291491 (opens in a new tab)DOI10.1111/dme.14655 (opens in a new tab)PepBankPUB-34291491
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanObservational studyEfficacy outcome

    In GLP-1RA-experienced persons with type 2 diabetes, once-weekly semaglutide lowered HbA1c by 0.6% after 12 months (p < 0.01).

    In plain wordsIn people with type 2 diabetes who had used GLP-1 drugs before, once-weekly semaglutide was linked to a 0.6% lower HbA1c after 12 months.

    Peptide
    Semaglutide
    Outcome
    DecreaseHbA1c change after 12 months, GLP-1RA experienced persons
    Study

    n = 82

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · subcutaneous · 12 monthsAs given in this study (human).

    Measurements

    HbA1c change
    −0.6%
    GLP-1RA experienced, 12 months
    HbA1c change
    −6.4 mmol/mol
    GLP-1RA experienced, 12 months

    Source sentences

    Summary
    After 12 months, the reductions in HbA1c were (mean [95% confidence interval]: GLP-1RA naïve: -12.8 [-17.0, -8.5] mmol/mol/ -1.2 [-1.6, -0.8]% (p < 0.01) and GLP-1RA experienced: -6.4 [-9.0, -3.8] mmol/mol/ -0.6 [-0.8, -0.4]% (p < 0.01), respectively.
    1 context sentence
    Summary · context
    This retrospective observational cohort study included persons with type 2 diabetes (n = 119) on a broad range of antidiabetic medicine: GLP-1RA naïve persons (n = 37) and GLP-1RA-experienced persons (n = 82).
  2. 02HumanObservational studyEfficacy outcome

    In GLP-1RA-experienced persons with type 2 diabetes, once-weekly semaglutide lowered body weight by 3.2 kg after 12 months (p < 0.01).

    In plain wordsIn people with type 2 diabetes who had used GLP-1 drugs before, once-weekly semaglutide was linked to about 3.2 kg weight loss after 12 months.

    Peptide
    Semaglutide
    Outcome
    DecreaseBody weight change after 12 months, GLP-1RA experienced persons
    Study

    n = 82

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · subcutaneous · 12 monthsAs given in this study (human).

    Measurements

    Body weight change
    −3.2 kg
    GLP-1RA experienced, 12 months

    Source sentences

    Summary
    Body weight reductions in GLP-1RA naïve: -5 [-6.9, -3.1] kg (p < 0.01) and GLP-1RA experienced: -3.2 [-4.4, -2.0] kg (p < 0.01), respectively.
    1 context sentence
    Summary · context
    This retrospective observational cohort study included persons with type 2 diabetes (n = 119) on a broad range of antidiabetic medicine: GLP-1RA naïve persons (n = 37) and GLP-1RA-experienced persons (n = 82).
  3. 03HumanObservational studyEfficacy outcome

    In GLP-1RA-naive persons with type 2 diabetes, once-weekly semaglutide lowered HbA1c by 1.2% after 12 months (p < 0.01).

    In plain wordsIn people with type 2 diabetes new to GLP-1 drugs, once-weekly semaglutide was linked to a 1.2% lower HbA1c after 12 months.

    Peptide
    Semaglutide
    Outcome
    DecreaseHbA1c change after 12 months, GLP-1RA naive persons
    Study

    n = 37

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · subcutaneous · 12 monthsAs given in this study (human).

    Measurements

    HbA1c change
    −1.2%
    GLP-1RA naive, 12 months
    HbA1c change
    −12.8 mmol/mol
    GLP-1RA naive, 12 months

    Source sentences

    Summary
    After 12 months, the reductions in HbA1c were (mean [95% confidence interval]: GLP-1RA naïve: -12.8 [-17.0, -8.5] mmol/mol/ -1.2 [-1.6, -0.8]% (p < 0.01) and GLP-1RA experienced: -6.4 [-9.0, -3.8] mmol/mol/ -0.6 [-0.8, -0.4]% (p < 0.01), respectively.
    1 context sentence
    Summary · context
    This retrospective observational cohort study included persons with type 2 diabetes (n = 119) on a broad range of antidiabetic medicine: GLP-1RA naïve persons (n = 37) and GLP-1RA-experienced persons (n = 82).
  4. 04HumanObservational studyEfficacy outcome

    In GLP-1RA-naive persons with type 2 diabetes, once-weekly semaglutide lowered body weight by 5 kg after 12 months (p < 0.01).

    In plain wordsIn people with type 2 diabetes new to GLP-1 drugs, once-weekly semaglutide was linked to about 5 kg weight loss after 12 months.

    Peptide
    Semaglutide
    Outcome
    DecreaseBody weight change after 12 months, GLP-1RA naive persons
    Study

    n = 37

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · subcutaneous · 12 monthsAs given in this study (human).

    Measurements

    Body weight change
    −5 kg
    GLP-1RA naive, 12 months

    Source sentences

    Summary
    Body weight reductions in GLP-1RA naïve: -5 [-6.9, -3.1] kg (p < 0.01) and GLP-1RA experienced: -3.2 [-4.4, -2.0] kg (p < 0.01), respectively.
    1 context sentence
    Summary · context
    This retrospective observational cohort study included persons with type 2 diabetes (n = 119) on a broad range of antidiabetic medicine: GLP-1RA naïve persons (n = 37) and GLP-1RA-experienced persons (n = 82).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:50 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.